Publications by authors named "Inge Zomerdijk"

Claim this Profile
R
Risk Minimisation Measures of Advanced Therapy Medicinal Products Authorised in the EU Between 2009 and 2023: A Cross-Sectional Study.
Sharon C M Essink, Inge M Zomerdijk, Sabine M J M Straus, Helga Gardarsdottir, Marie L De Bruin

Drug Saf· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Duration of Time Intervals for Risk Minimization Measure Effectiveness Studies.
Sharon C M Essink, Inge M Zomerdijk, Thomas Goedecke, Sabine M J M Straus, Helga Gardarsdottir

Clin Pharmacol Ther· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Duration of Effectiveness Evaluation of Additional Risk Minimisation Measures for Centrally Authorised Medicinal Products in the EU Between 2012 and 2021.
Sharon C M Essink, Inge M Zomerdijk, Sabine M J M Straus, Helga Gardarsdottir, Marie L De Bruin

Drug Saf· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Introduction or Discontinuation of Additional Risk Minimisation Measures During the Life Cycle of Medicines in Europe.
Reynold D C Francisca, Emna Baba, Christina E Hoeve, Inge M Zomerdijk, Miriam C J M Sturkenboom

Drug Saf· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Description of the Risk Management of Medication Errors for Centrally Authorised Products in the European Union.
Christina E Hoeve, Reynold D C Francisca, Inge Zomerdijk, Miriam C J M Sturkenboom, Sabine M J M Straus

Drug Saf· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Measuring the impact of the 2012 European pharmacovigilance legislation on additional risk minimization measures.
Reynold D C Francisca, Inge M Zomerdijk, Miriam C J M Sturkenboom, Sabine M J M Straus

Expert Opin Drug Saf· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A comparison of pregnancy prevention programmes in Europe.
Ineke Crijns, Inge Zomerdijk, Miriam Sturkenboom, Lolkje de Jong-van den Berg, Sabine Straus

Expert Opin Drug Saf· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Post-approval evaluation of effectiveness of risk minimisation: methods, challenges and interpretation.
Anjan Kumar Banerjee, Inge M Zomerdijk, Stella Wooder, Simon Ingate, Stephen J Mayall

Drug Saf· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Additional risk minimisation measures in the EU - are they eligible for assessment?
Inge M Zomerdijk, Gianluca Trifirò, Fakhredin A Sayed-Tabatabaei, Miriam C J M Sturkenboom, Sabine M J M Straus

Pharmacoepidemiol Drug Saf· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk minimization activities of centrally authorized products in the EU: a descriptive study.
Inge M Zomerdijk, Fakhredin A Sayed-Tabatabaei, Gianluca Trifirò, Stella C F Blackburn, Miriam C J M Sturkenboom

Drug Saf· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis